

BIODELIVERY SCIENCES INTERNATIONAL INC  
Form SC 13D/A  
July 17, 2009

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO  
FILED PURSUANT TO RULE 13d-2(a)

(Amendment No. 4)\*

BioDelivery Sciences International, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

09060J106

(CUSIP Number)

Stephen M. Schultz, Esq.

Kleinberg, Kaplan, Wolff & Cohen, P.C.

551 Fifth Avenue, New York, New York 10176

Tel: (212) 986-6000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

July 16, 2009

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box o.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13D/A

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see the Notes*).

---

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13D/A

1. NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Elliott Associates, L.P.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)  X

(b)  O

3. SEC USE ONLY

4. SOURCE OF FUNDS\*

WC

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  O

6. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7. SOLE VOTING POWER

2,665,350

8. SHARED VOTING POWER

0

9. SOLE DISPOSITIVE POWER

2,665,350

10. SHARED DISPOSITIVE POWER

0

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,665,350

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)

EXCLUDES CERTAIN SHARES\*  O

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

12.3%

14. TYPE OF REPORTING PERSON\*

PN

**\*SEE INSTRUCTIONS BEFORE FILLING OUT!**

---

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13D/A

1. NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Elliott International, L.P.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)  X

(b)  O

3. SEC USE ONLY

4. SOURCE OF FUNDS\*

WC

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  O

6. CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands, British West Indies

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7. SOLE VOTING POWER

0

8. SHARED VOTING POWER

240,345

9. SOLE DISPOSITIVE POWER

0

10. SHARED DISPOSITIVE POWER

240,345

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

240,345

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)

EXCLUDES CERTAIN SHARES\*  O

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

1.1%

14. TYPE OF REPORTING PERSON\*

PN

**\*SEE INSTRUCTIONS BEFORE FILLING OUT!**

---

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13D/A

1. NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Elliott International Capital Advisors Inc.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)  X  
(b)  O

3. SEC USE ONLY  
4. SOURCE OF FUNDS\*  
OO

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  O  
6. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7. SOLE VOTING POWER  
0

8. SHARED VOTING POWER  
240,345

9. SOLE DISPOSITIVE POWER  
0

10. SHARED DISPOSITIVE POWER  
240,345

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
240,345

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)  
EXCLUDES CERTAIN SHARES\*  O

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
1.1%

14. TYPE OF REPORTING PERSON\*  
CO

**\*SEE INSTRUCTIONS BEFORE FILLING OUT!**

---

## Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13D/A

This statement is filed with respect to the shares of the common stock, \$0.001 par value (the "Common Stock"), of BioDelivery Sciences International, Inc. (the "Issuer"), beneficially owned by Elliott Associates, L.P. and its wholly-owned subsidiaries ("Elliott"), Elliott International, L.P. ("Elliott International"), and Elliott International Capital Advisers Inc. ("EICA" and collectively, the "Reporting Persons") as of July 16, 2009 and amends and supplements the Schedule 13D filed on August 23, 2006, as amended on June 17, 2009, June 22, 2009 and July 7, 2009 (the "Schedule 13D"). Except as set forth herein, the Schedule 13D is unmodified.

### **ITEM 5. Interest in Securities of the Issuer.**

(a) Elliott owns 160,230 shares of Common Stock through a wholly-owned subsidiary, The Liverpool Limited Partnership. Elliott may also be deemed to be the beneficial owner of an additional 2,505,120 shares of Common Stock beneficially owned by CDC IV, LLC consisting of warrants held by CDC IV, LLC exercisable for 2,505,120 shares of Common Stock ("Warrants"). As described in the Schedule 13D, Manchester has investment discretion with respect to the Warrants. Therefore, Elliott may be deemed to be the beneficial owner of an aggregate of 2,665,350 shares of Common Stock, constituting 12.3% of all of the outstanding shares of Common Stock.

Elliott International and EICA beneficially own an aggregate of 240,345 shares of Common Stock, constituting 1.1% of all of the outstanding shares of Common Stock.

The stock ownership reported in this paragraph (a) of Item 5 are as of July 16, 2009.

(b) Elliott has the power to vote or direct the vote of, and to dispose or direct the disposition of, the shares of Common Stock beneficially owned by it.

Elliott International has the shared power with EICA to vote or direct the vote of, and to dispose or direct the disposition of, the shares of Common Stock owned by Elliott International. Information regarding each of Elliott International and EICA is set forth in Item 2 of this Schedule 13D and is expressly incorporated by reference herein.

(c) A list of the transactions in the Issuer's Common Stock that were effected by Elliott on behalf of CDC IV during the past sixty days is attached hereto as Appendix I, except for those previously reported on this Schedule 13D. A list of the transactions in the Issuer's Common Stock that were effected by The Liverpool Limited Partnership on its own behalf is attached hereto as Appendix II and a list of the transactions in the Issuers Common Stock that were effected by Elliott International on its own behalf are set forth on Appendix III.

(d) Except for the the Warrants, no person other than Elliott has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock beneficially owned by Elliott.

No person other than Elliott International and EICA has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock beneficially owned by Elliott International and EICA.

(e) Not applicable.

### **Item 7. Material to Be Filed as Exhibits**

The following documents are filed as exhibits:

---

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13D/A

Appendix I: List of the transactions in the Issuer's Common Stock that were effected by Manchester on behalf of CDC IV during the past sixty days except for those previously reported on this Schedule 13D.

Appendix II: List of the transactions in the Issuer's Common Stock that were effected by The Liverpool Limited Partnership on its own behalf during the past sixty days except for those previously reported on this Schedule 13D.

Appendix III: List of the transactions in the Issuer's Common Stock that were effected by Elliott International on its own behalf during the past sixty days except for those previously reported on this Schedule 13D.

**SIGNATURES**

After reasonable inquiry and to the best of its knowledge and belief, the undersigned each certifies that the information with respect to it set forth in this statement is true, complete and correct.

Dated: July 17, 2009

ELLIOTT ASSOCIATES, L.P.

By: Elliott Capital Advisors, L.P., as General Partner

By: Braxton Associates, Inc., as General Partner

By: /s/ Elliot Greenberg

Elliot Greenberg,

Vice President

ELLIOTT INTERNATIONAL, L.P.

By: Elliott International Capital Advisors Inc.,

as Attorney-in-Fact

By: /s/ Elliot Greenberg

Elliot Greenberg,

Vice President

ELLIOTT INTERNATIONAL CAPITAL ADVISORS INC.

By: /s/ Elliot Greenberg

Elliot Greenberg,

Vice President

## APPENDIX I

## LIST OF TRANSACTIONS

Transactions Effected by Manchester on behalf of CDC IV in Common Stock during the past sixty days:

Date of transaction	Amount of securities	Price per share or unit (excluding commissions)	Where and how the transaction was effected
	Sold		
7/7/09	1,510	\$6.1000	Open Market
7/7/09	1,200	\$6.1100	Open Market
7/7/09	2,263	\$6.1200	Open Market
7/7/09	7,335	\$6.1300	Open Market
7/7/09	850	\$6.1500	Open Market
7/8/09	261	\$6.2500	Open Market
7/15/09	1,807	\$6.0075	Open Market
7/15/09	2,700	\$6.0100	Open Market
7/15/09	400	\$6.0200	Open Market
7/15/09	300	\$6.0050	Open Market
7/15/09	22,563	\$6.0000	Open Market
7/16/09	2,150	\$6.0000	Open Market
7/16/09	805	\$6.0200	Open Market
7/16/09	100	\$6.7050	Open Market
7/16/09	11,600	\$6.7500	Open Market
7/16/09	1,000	\$6.7800	Open Market
7/16/09	10,800	\$6.7000	Open Market
7/16/09	1,500	\$6.7100	Open Market
7/16/09	1,200	\$6.8300	Open Market
7/16/09	500	\$6.8100	Open Market
7/16/09	700	\$6.8200	Open Market
7/16/09	22,600	\$6.8000	Open Market
7/16/09	10,500	\$6.9000	Open Market
7/16/09	4,100	\$6.8700	Open Market
7/16/09	6,500	\$6.8500	Open Market
7/16/09	400	\$6.8600	Open Market
7/16/09	2,600	\$6.8800	Open Market
7/16/09	100	\$6.9100	Open Market
7/16/09	800	\$6.9400	Open Market
7/16/09	25,000	\$7.0000	Open Market
7/16/09	300	\$7.1350	Open Market
7/16/09	700	\$7.1400	Open Market
7/16/09	2,300	\$7.1600	Open Market
7/16/09	6,647	\$7.1200	Open Market
7/16/09	18,472	\$7.1100	Open Market

---



**APPENDIX II**

**LIST OF TRANSACTIONS**

Transactions Effected by The Liverpool Limited Partnership in Common Stock during the past sixty days:

Date of transaction	Amount of securities	Price per share or unit (excluding commissions)	Where and how the transaction was effected
	Sold		
7/16/09	17	\$6.3700	Open Market
7/16/09	9,568	\$6.5000	Open Market
7/16/09	2,800	\$6.6000	Open Market
7/16/09	555	\$7.1200	Open Market
7/16/09	1,460	\$7.1600	Open Market
7/16/09	600	\$7.1700	Open Market

---

**APPENDIX III**

**LIST OF TRANSACTIONS**

Transactions Effected by EICA in Common Stock during the past sixty days:

Date of transaction	Amount of securities	Price per share or unit (excluding commissions)	Where and how the transaction was effected
	Sold		
7/16/09	24	\$6.3700	Open Market
7/16/09	14,353	\$6.5000	Open Market
7/16/09	4,200	\$6.6000	Open Market
7/16/09	833	\$7.1200	Open Market
7/16/09	2,190	\$7.1600	Open Market
7/16/09	900	\$7.1700	Open Market